The biggest pharmaceutical drug companies in the world are shedding millions of dollars a year.
A Reuters investigation found that as many as 1.5 million pharmaceutical companies have lost money in 2015, a year that saw the first half of that year marked by an outbreak of H1N1 influenza.
While the companies were not named, Reuters identified seven of the biggest companies that were shedding billions of dollars, including Merck, Bristol-Myers Squibb, Pfizer, Johnson & Johnson and Abbott Laboratories.
The companies are among the biggest and most profitable pharmaceutical companies in Asia, accounting for about 10 percent of global sales, according to a Reuters review of industry reports and regulatory filings.
Their business models depend on drug pricing.
Pharmaceutical companies, like any business, charge drugmakers for a drug that can help prevent a disease.
For years, the companies have charged high prices to patients, and often charge huge discounts for the medicines that help fight the disease.
For example, for the first six months of 2015, Merck charged a $9,000 drug for a generic version of its H1n1 flu vaccine, compared with $8,500 for a brand-name version.
At the same time, the cost of drugs to make H1Ns has risen to more than $100,000 a year, according the National Academies of Science and Medicine.
Pharmaceuticals also have been losing money on vaccines because of new strains of the H1s.
In an effort to keep up with the rise in H1NP prices, drugmakers have been charging more and more for the vaccine, which was the second-most-expensive vaccine in the US in 2015.
The price of flu vaccines has risen rapidly over the past two years because of the emergence of a new strain of the virus that was harder to fight than the original H1.
The price for a flu vaccine has soared to about $300 a shot in the United States, about 30 percent more than the previous year.
The increase in price was partly due to a surge in the prices of several vaccines.
One of the major culprits was the introduction of a cheaper H1 vaccine in 2018, which increased the cost by more than 30 percent in the first two years of the year, the researchers wrote.
The new vaccine also contained less of the protein in the vaccine that makes it more effective against the H2N2 influenza strain.
This means it doesn’t make the H4N2 virus less aggressive.
But it also increased the costs of the other vaccines, which made it more expensive for patients to get them, the scientists said.
The rise in the price of vaccines meant that the price for patients with the H5N1 virus was going up by more $500 a year compared with last year.
It also meant that people were getting less of their flu shots than they had before.